Пожалуйста, используйте этот идентификатор, чтобы цитировать или ссылаться на этот ресурс:
http://elar.urfu.ru/handle/10995/103195
Название: | Defining muscle-invasive bladder cancer immunotypes by introducing tumor mutation burden, CD8+ T cells, and molecular subtypes |
Авторы: | Chen, Z. Liu, G. Liu, G. Bolkov, M. A. Shinwari, K. Tuzankina, I. A. Chereshnev, V. A. Wang, Z. |
Дата публикации: | 2021 |
Издатель: | BioMed Central Ltd |
Библиографическое описание: | Defining muscle-invasive bladder cancer immunotypes by introducing tumor mutation burden, CD8+ T cells, and molecular subtypes / Z. Chen, G. Liu, G. Liu, et al. — DOI 10.1186/s41065-020-00165-7 // Hereditas. — 2021. — Vol. 158. — Iss. 1. — 1. |
Аннотация: | Immunotherapy, especially anti-PD-1, is becoming a pillar of modern muscle-invasive bladder cancer (MIBC) treatment. However, the objective response rates (ORR) are relatively low due to the lack of precise biomarkers to select patients. Herein, the molecular subtype, tumor mutation burden (TMB), and CD8+ T cells were calculated by the gene expression and mutation profiles of MIBC patients. MIBC immunotypes were constructed using clustering analysis based on tumor mutation burden, CD8+ T cells, and molecular subtypes. Mutated genes, enriched functional KEGG pathways and GO terms, and co-expressed network-specific hub genes have been identified. We demonstrated that ORR of immunotype A patients identified by molecular subtype, CD8+ T cells, and TMB is about 36% predictable. PIK3CA, RB1, FGFR3, KMT2C, MACF1, RYR2, and EP300 are differentially mutated among three immunotypes. Pathways such as ECM-receptor interaction, PI3K-Akt signaling pathway, and TGF-beta signaling pathway are top-ranked in enrichment analysis. Low expression of ACTA2 was associated with the MIBC survival benefit. The current study constructs a model that could identify suitable MIBC patients for immunotherapy, and it is an important step forward to the personalized treatment of bladder cancers. © 2021, The Author(s). |
Ключевые слова: | CD8+ T CELLS IMMUNOTHERAPY IMMUNOTYPE MIBC MOLECULAR SUBTYPE TMB ATEZOLIZUMAB E1A ASSOCIATED P300 PROTEIN FIBROBLAST GROWTH FACTOR RECEPTOR 3 PHOSPHATIDYLINOSITOL 3 KINASE PROTEIN KINASE B RYANODINE RECEPTOR 2 TRANSFORMING GROWTH FACTOR BETA TUMOR MARKER ADULT ARTICLE CANCER CLASSIFICATION CANCER IMMUNOTHERAPY CANCER PATIENT CANCER SURVIVAL CD8+ T LYMPHOCYTE CELL INFILTRATION CLINICAL TRIAL (TOPIC) DATA ANALYSIS SOFTWARE GENE EXPRESSION GENE MUTATION GENE ONTOLOGY HUMAN HUMAN CELL MOLECULAR SUBTYPE MUSCLE INVASIVE BLADDER CANCER ONCOLOGICAL PARAMETERS OVERALL SURVIVAL PI3K/AKT SIGNALING TGF BETA SIGNALING TUMOR MUTATION BURDEN |
URI: | http://elar.urfu.ru/handle/10995/103195 |
Условия доступа: | info:eu-repo/semantics/openAccess |
Идентификатор SCOPUS: | 85098627194 |
Идентификатор WOS: | 000606479600001 |
Идентификатор PURE: | 20382726 355d1a0b-a6ea-4399-80e2-41498fb9679e |
ISSN: | 180661 |
DOI: | 10.1186/s41065-020-00165-7 |
Сведения о поддержке: | This study was funded by the Act 211 Government of the Russian Federation (No.02.A03.21.0006) and the IIP UB RAS project (No.AAAA-A18–118020590108-7). |
Располагается в коллекциях: | Научные публикации ученых УрФУ, проиндексированные в SCOPUS и WoS CC |
Файлы этого ресурса:
Файл | Описание | Размер | Формат | |
---|---|---|---|---|
2-s2.0-85098627194.pdf | 4,2 MB | Adobe PDF | Просмотреть/Открыть |
Все ресурсы в архиве электронных ресурсов защищены авторским правом, все права сохранены.